<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Sch of Chemistry</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9D0C6264-3B3A-41E7-940F-4A66DC7E7D95"><gtr:id>9D0C6264-3B3A-41E7-940F-4A66DC7E7D95</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44"><gtr:id>D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Nelson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FD069521%2F1"><gtr:id>E110F1D3-D2BB-45A0-9A83-55918B2E463F</gtr:id><gtr:title>Combined use of organo- and enzymic catalysis in three component couplings: Building blocks for bioactive molecule synthesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/D069521/1</gtr:grantReference><gtr:abstractText>The preparation of biological molecules, such as drugs and agrochemicals, generally involves many separate synthetic steps. At the end of each step, an intermediate is usually purified before functionalisation in the next step. To improve the efficiency of the construction of such molecules, the number of separate reactions and purifications would need to be reduced. This proposal will generate new methods which will allow more than one step to be performed in a single reaction vessel. This approach is broadly analogous to would involve the concatenation of several steps Nature: metabolic pathways involve the processing of reaction intermediate by compatible (enzyme) catalysts in a single reaction vessel (the cell). The products of the new methodology will be exploited in the synthesis of building blocks for preparation of biologically active molecules.</gtr:abstractText><gtr:fund><gtr:end>2009-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2006-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99746</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK enzymes</gtr:description><gtr:id>41552122-5ABA-4AFD-BA2C-B20B84884E1F</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>545b51fd0a8d11.79289120-1</gtr:outcomeId><gtr:partnerContribution>Supervision. Input to project</gtr:partnerContribution><gtr:piContribution>Development of chemically-modified enzymes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AZ enzyme</gtr:description><gtr:id>16E569E3-5896-485C-A040-2D30167DEC91</gtr:id><gtr:impact>A paper.</gtr:impact><gtr:outcomeId>545b5009bd7398.21843530-1</gtr:outcomeId><gtr:partnerContribution>Supervison. Input to project</gtr:partnerContribution><gtr:piContribution>Development of enzymes for synthesis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI CHEM21 consortium</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>CD76BF3C-BEDF-4A54-8113-59A9189D1951</gtr:id><gtr:outcomeId>545b533696fcd5.69877306</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3C55BD7F-ED43-4E3F-8189-A0E29E1DDE2D</gtr:id><gtr:title>Development of an organo- and enzyme-catalysed one-pot, sequential three-component reaction</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f9471d2fb3506b3e45c5f4e1c057a8"><gtr:id>21f9471d2fb3506b3e45c5f4e1c057a8</gtr:id><gtr:otherNames>Kinnell A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d00c00cf5a7260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C12B1A4-F8CC-49D6-9894-D7090183ECB3</gtr:id><gtr:title>Engineering aldolases as biocatalysts.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/527f9e2a42d38d46a9b4459ffc8ac3db"><gtr:id>527f9e2a42d38d46a9b4459ffc8ac3db</gtr:id><gtr:otherNames>Windle CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn><gtr:outcomeId>545b438386acc8.28755948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4681BB83-8395-4BB2-BB1A-8C60B9FB0BEF</gtr:id><gtr:title>Structural insights into substrate specificity in variants of N-acetylneuraminic Acid lyase produced by directed evolution.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db75319450eac8e317e9f4bc9b32f0f1"><gtr:id>db75319450eac8e317e9f4bc9b32f0f1</gtr:id><gtr:otherNames>Campeotto I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>doi_53cffcffc145e9f0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/D069521/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>